MYC and Miyoshi myopathy: In order to evaluate whether pharmacologic activation of STING could augment antimyeloma activity of bortezomib in vivo, we chose syngeneic Vκ*MYC immunocompetent MM murine model [14], that lacks STING expression (Supplementary Fig. 7).